Back Jazz Pharmaceuticals German جاز فارماستیکال Persian Jazz Pharmaceuticals French Jazz Pharmaceuticals Russian
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | |
| Company type | Public |
|---|---|
| Industry | |
| Predecessor | Jazz Pharmaceuticals, Inc. (before the 2012 tax inversion to Ireland) |
| Founded | 2003 in California, U.S. |
| Headquarters | Dublin, Ireland |
Area served | Worldwide |
Key people | Bruce C. Cozadd (chairman and CEO) |
| Products | Pharmaceutical drugs |
| Brands | |
| Revenue |  US$3.83 billion (2023) |
| US$579 million (2023) | |
| US$415 million (2023) | |
| Total assets | US$11.4 billion (2023) |
| Total equity | US$3.74 billion (2023) |
Number of employees | c. 2,800 (2023) |
| Website | jazzpharma |
| Footnotes / references [1] | |
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States.[2] One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales.[1] In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.[3]
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.[4]
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[5]
- ^ a b "Jazz Pharmaceuticals PLC 2023 Annual Report (Form 10-K)". sec.gov. U.S. Securities and Exchange Commission. 28 February 2024. Retrieved 28 February 2024.
- ^ "History". Jazz Pharmaceuticals. Archived from the original on 23 November 2016. Retrieved 22 November 2016.
- ^ "Axsome To Buy Sunosi From Jazz". NASDAQ. Retrieved 28 March 2022.
- ^ "Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in "Off-label" Marketing Investigation". Archived from the original on 2021-07-20. Retrieved 2016-06-08.
- ^ "Teva wins controversial PhRMA bid despite protests from branded rivals". 18 July 2016. Archived from the original on 19 July 2016. Retrieved 18 July 2016.